SciTech Development, Inc. Receives Drug Supply from NCI

SciTech Development, Inc., a biotechnology firm in the clinical stages of advancing cancer therapeutics, has received significant support from the National Cancer Institute (NCI), an agency within the National Institutes of Health. The NCI has supplied the company with additional fenretinide, a crucial component of SciTech's investigational drug, ST-001. This provision will enable the company to treat over 300 patients and facilitate the completion of both Phase 1a and 1b clinical trials across six different locations, further expanding their clinical research.

The additional fenretinide supply will be pivotal in achieving key objectives in Phase 1 trials. These goals include determining the optimal dosage of the drug and evaluating its safety and tolerability in patients who have relapsed or have refractory T-cell non-Hodgkin lymphoma. The supplemental supply not only aids in achieving these clinical milestones but also reduces the overall development costs and expedites the timeline for the drug’s progress.

Earle Holsapple, the CEO of SciTech Development, expressed gratitude for the NCI's support. He emphasized that this endorsement underscores the potential of ST-001 in treating a variety of cancers, with an initial focus on T-cell lymphoma. Holsapple highlighted that the additional fenretinide supply would aid the company in advancing its clinical programs seamlessly, allowing them to complete both phases of their trial. This marks a significant step toward providing a new therapeutic option for patients dealing with hard-to-treat cancers.

ST-001 is unique due to its innovative formulation. It is a patented, aqueous suspension of nanoparticles containing fenretinide encapsulated within specially designed phospholipid bilayers. This formulation aims to enhance the drug's bioavailability, delivery, and overall efficacy in cancer treatment. Fenretinide itself has been extensively researched and is known for its multiple anti-cancer mechanisms, favorable safety profile, and potential applicability in treating various other cancers.

SciTech Development remains committed to delivering cutting-edge therapies to patients in need and appreciates the NCI's ongoing support. The company is eager to share further updates as their clinical trials progress.

SciTech Development, Inc., is dedicated to developing new therapies for cancer treatment and is working diligently to advance its clinical programs to provide innovative and effective treatments to patients globally.